



The Relationship Between Antiretroviral Therapy Initiation and the Development of Immune Reconstitution Inflammatory Syndrome: A Review of Foundational Concepts

¹A.Deloach, ²A.Davis

^{1,2} University of Illinois College of Medicine

Corresponding Email : deloachmd827474@gmail.com

Article History :

Received date : 2023/10/12
Revised date : 2023/11/28
Accepted date : 2023/12/09
Published date : 2024/01/13



Copyright: © by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (<https://creativecommons.org/licenses/by-nc/4.0/>).

ABSTRACT

Introduction: The introduction of effective antiretroviral therapy (ART) transformed the prognosis for patients with HIV, allowing for robust restoration of the immune system. However, this immune recovery can precipitate a paradoxical clinical worsening known as Immune Reconstitution Inflammatory Syndrome (IRIS), a significant complication of treatment initiation.

Literature Review: A review of the pivotal literature defines IRIS as an aberrant and exaggerated inflammatory response directed against underlying opportunistic pathogens, which is "unmasked" following the start of ART. The pathogenesis is attributed to the rapid quantitative and qualitative recovery of the immune system, particularly pathogen-specific CD4⁺ T-cells, leading to a surge of pro-inflammatory cytokines. Foundational clinical studies identified the primary risk factors for developing IRIS, including a very low baseline CD4⁺ T-cell count and the presence of a high burden of an opportunistic infection at the time ART is

commenced. The clinical dilemma of when to initiate ART in patients with active co-infections, most notably tuberculosis, became a central challenge, requiring a careful balance between the risk of IRIS and the risk of ongoing immunodeficiency.

Conclusion: The body of evidence established IRIS as a common and clinically important consequence of successful ART. This research was essential for defining the syndrome, understanding its immunopathology, and developing clinical strategies to anticipate and manage this paradoxical complication in patients with advanced HIV disease.

Keywords: Immune Reconstitution Inflammatory Syndrome (IRIS), Antiretroviral Therapy (ART), HIV, Tuberculosis, Opportunistic Infections.

INTRODUCTION

The advent of potent combination antiretroviral therapy (ART) represented a watershed moment in the history of medicine, converting HIV infection from a near-uniformly fatal illness into a chronic, manageable condition. By effectively suppressing HIV replication, ART allows for a significant and sustained recovery of the host's immune system, primarily reflected by a rise in the CD4⁺ T-lymphocyte count. While this immune restoration is the central goal of therapy and is responsible for dramatically reducing AIDS-defining illnesses and death, it can also produce unexpected and paradoxical clinical consequences.

One of the most important of these consequences is the Immune Reconstitution Inflammatory Syndrome (IRIS), also known as immune restoration disease. IRIS refers to a collection of inflammatory disorders associated with a paradoxical worsening of a pre-existing infection or the appearance of a previously subclinical infection that occurs soon after initiating ART. This literature review aims to synthesise the foundational scientific and clinical publications that defined the IRIS phenomenon, explored its underlying pathogenesis, and identified the key risk factors for its development.

LITERATURE REVIEW

The understanding of IRIS as a distinct clinical entity was consolidated through descriptive studies, mechanistic research, and risk factor analyses.

First, the clinical spectrum of the syndrome was defined. Literature from this period formally characterized IRIS as presenting in two main forms. "Unmasking" IRIS occurs when the

recovering immune system reveals a previously undiagnosed, subclinical opportunistic infection, leading to the sudden onset of inflammatory symptoms. "Paradoxical" IRIS describes the situation where a patient who has been diagnosed and is improving on treatment for an opportunistic infection experiences a sudden clinical worsening after ART is started (Shelburne and Hamill, 2003). While IRIS was described in association with a wide range of pathogens including cytomegalovirus and cryptococcus, it was most commonly and intensively studied in the context of *Mycobacterium tuberculosis* co-infection, reflecting the global syndemic of HIV and tuberculosis (Lawn et al., 2005).

The immunopathogenesis of IRIS was elucidated as a consequence of a rapid but dysregulated immune recovery. The core mechanism is not the pathogen itself, but the host's aberrant inflammatory response to it. Before ART, in a state of severe immunosuppression, the host cannot mount an effective inflammatory response, allowing opportunistic pathogens to replicate with minimal clinical signs. The initiation of ART leads to a rapid decline in HIV viral load and a sharp increase in the number and function of immune cells, especially memory CD4⁺ T-cells. This newly restored immune system now recognizes the high burden of pathogen antigens, triggering a massive and often excessive, pathogen-specific inflammatory response. This response is characterized by a surge in pro-inflammatory cytokines like interferon-gamma and TNF-alpha, which drives the clinical signs of inflammation, such as fever, lymphadenopathy, and worsening organ dysfunction (French et al., 2004).

Observational cohort studies were crucial in identifying the major risk factors for developing IRIS. The most consistent predictors found were those indicative of severe pre-existing immunodeficiency and a high underlying pathogen load. A very low baseline CD4⁺ T-cell count (e.g., <50 cells/ μ L) at the time of ART initiation was the single strongest risk factor. Other identified risks included a rapid decline in HIV viral load and a steep rise in CD4⁺ T-cell count after starting therapy, confirming that the rapidity of immune restoration is a key element (Breton et al., 2004).

The high incidence and potential severity of Tuberculosis-Associated IRIS (TB-IRIS) created a major clinical dilemma for providers, particularly in resource-limited settings. Clinicians faced a difficult choice: initiating ART early in the course of TB treatment could hasten immune recovery and reduce the risk of other HIV-related complications, but it carried a very high risk of precipitating severe or even fatal TB-IRIS. Conversely, delaying ART would lower the risk

of IRIS but would leave the profoundly immunosuppressed patient at high risk of death from HIV progression or other opportunistic infections. This critical question of timing became a central focus of clinical research (Meintjes et al., 2008).

CONCLUSION

The pivotal literature on Immune Reconstitution Inflammatory Syndrome established it as a critical and common complication of the very success of antiretroviral therapy. It is not a drug toxicity, but rather an iatrogenic syndrome resulting from an exuberant but poorly regulated immune response to opportunistic pathogens in a host whose immune system is rapidly recovering. The research from this period was essential in defining its clinical presentations, uncovering its immunopathological basis, and identifying the patient populations at highest risk—namely, those with the most advanced immunodeficiency.

Understanding IRIS became indispensable for clinicians managing HIV worldwide. The body of work taught providers to anticipate this paradoxical worsening, to distinguish it from treatment failure or a new infection, and to navigate the complex risk-benefit decisions surrounding the timing of ART initiation in patients with major co-infections like tuberculosis. This knowledge was fundamental to improving the safety and efficacy of the global scale-up of life-saving antiretroviral therapy.

REFERENCES

- Breton, G., Duval, X., Estellat, C., Poalletti, X., Bonnet, D., Mvondo, D., Longuet, P., Leport, C. and Vildé, J.L. (2004) 'Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after starting antiretroviral therapy', *Clinical Infectious Diseases*, 39(11), pp. 1709-1712.
- French, M.A., Price, P. and Stone, S.F. (2004) 'Immune restoration disease after antiretroviral therapy', *AIDS*, 18(12), pp. 1615-1627.
- Lawn, S.D., Bekker, L.G. and Miller, R.F. (2005) 'Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals', *The Lancet Infectious Diseases*, 5(6), pp. 361-373.
- Meintjes, G., Lawn, S.D., Scano, F., Maartens, G., French, M.A., Worodria, W., Elliott, J.H., Murdoch, D., Wilkinson, R.J., Miro, J.M., Gazzard, B., Reiss, P. and Stevens, W. (2008)

'Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings', *The Lancet Infectious Diseases*, 8(8), pp. 516-523.

Shelburne, S.A. and Hamill, R.J. (2003) 'The immune reconstitution inflammatory syndrome', *AIDS Reviews*, 5(2), pp. 67-79.